Identifying genetic markers for predicting heparin-induced thrombocytopenia
Pharmacogenomics of Heparin-Induced Thrombocytopenia
This study is trying to find genetic markers that can help predict if people will develop heparin-induced thrombocytopenia after using heparin.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Arizona Academic / other |
| Locations | 1 site (Tucson, Arizona) |
| Trial ID | NCT02717039 on ClinicalTrials.gov |
What this trial studies
This research aims to identify genomic markers that can predict the occurrence of heparin-induced thrombocytopenia (HIT), a serious side effect associated with heparin use. Participants aged 18 and older will be enrolled based on their heparin/PF4 antibody and serotonin release assay (SRA) test results. The study will categorize participants into three groups: controls with negative tests, seroconversion cases with positive antibodies but negative SRA, and HIT cases with positive results for both. Blood samples will be collected to analyze these genomic markers, with recruitment facilitated through the Coagulation Laboratory at Banner University Medical Center in Tucson.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have undergone testing for heparin/PF4 antibodies and have received heparin treatment.
Not a fit: Patients who are under 18 years of age or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prevention strategies for patients at risk of developing heparin-induced thrombocytopenia.
How similar studies have performed: While the approach of identifying genomic markers for HIT is innovative, similar studies have shown promise in other areas of pharmacogenomics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Ability to give informed consent * Have undergone testing for heparin/PF4 antibody with or without SRA testing for HIT * Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing Exclusion Criteria: * Less than 18 years of age * Pregnancy * Hemoglobin less than 9 mg/dL (for larger 5 ounce blood draw) * Known Human Immunodeficiency Virus (HIV) infection * Inability to give informed consent
Where this trial is running
Tucson, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona, United States (Recruiting)
Study contacts
- Study coordinator: Jason H Karnes, PharmD, PhD
- Email: karnes@pharmacy.arizona.edu
- Phone: 520-626-1447
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.